Quince Therapeutics, Inc.
QNCX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662774
No open-market purchases or sales by Quince Therapeutics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $4.74M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Quince Therapeutics, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +14 vs. Q1 2021
- Shares held
- 18.5M
- −147.7K (−0.8%) vs. Q1 2021
- Total value
- $982.9M
- +$309.4M (+45.9%) vs. Q1 2021
- New holders
- 26
- 40 more added
- Sold out
- 12
- 20 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting QNCX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 26 | $4.74M |
| Q1 2026 | 46 | $1.44M |
| Q4 2025 | 67 | $67.5M |
| Q3 2025 | 45 | $19.2M |
| Q2 2025 | 41 | $12.5M |
| Q1 2025 | 36 | $6.96M |
| Q4 2024 | 35 | $9.55M |
| Q3 2024 | 33 | $4.04M |
| Q2 2024 | 43 | $4.68M |
| Q1 2024 | 46 | $7.71M |
| Q4 2023 | 44 | $7.83M |
| Q3 2023 | 42 | $8.40M |
| Q2 2023 | 40 | $13.5M |
| Q1 2023 | 45 | $12.0M |
| Q4 2022 | 50 | $3.44M |
| Q3 2022 | 61 | $12.4M |
| Q2 2022 | 70 | $26.0M |
| Q1 2022 | 88 | $99.5M |
| Q4 2021 | 102 | $242.8M |
| Q3 2021 | 131 | $1.76B |
| Q2 2021 | 105 | $982.9M |
| Q1 2021 | 91 | $673.5M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Quince Therapeutics, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 1,284,572 | $68.1M | 0.00% | −77,965−5.7% | Reduced |
| Capital Research Global Investors | 2,315,839 | $122.7M | 0.03% | −289,914−11.1% | Reduced |
| Capital International Investors | 2,736,669 | $145.0M | 0.03% | +275,089+11.2% | Added |
| Capital World Investors | 3,327,402 | $176.4M | 0.03% | +2,373+0.1% | Added |
| EPIQ Capital Group, LLC | 3,765,505 | $199.6M | 20.85% | +109,706+3.0% | Added |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −32,717−100.0% | Sold out |
| California Public Employees Retirement System | 0 | $0 | 0.00% | −32,000−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −23,254−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −12,982−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −11,305−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −8,359−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −6,645−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −6,334−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −3,596−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −1,244−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −1,199−100.0% | Sold out |
| Sowell Financial Services LLC | 0 | $0 | 0.00% | −123−100.0% | Sold out |